RxDoctor Payments Data

Ahamed Jiffry, MD

Internal Medicine · San Bernardino, CANPI 1295848679

Payments from drug & device makers

$448in general payments, 2019–2025

Across 19 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$175
  • Bayer$124
  • Sanofi-aventis U.S. LLC$63
  • Johnson & Johnson$27
  • Lilly USA, LLC$19
  • Exact Sciences$17
  • plus $23 from 2 others

What the payments were for

  • Food & beverage$448100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$448 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$45,635
Medicare patients
100
Services billed
334

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin51$59,548
OzempicSemaglutide46$50,038
FarxigaDapagliflozin Propanediol55$49,767
JanuviaSitagliptin Phosphate29$31,091
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr37$23,050
EliquisApixaban37$19,857
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog53$18,855
Stiolto RespimatTiotropium Br/Olodaterol Hcl23$17,013
DapagliflozinDapagliflozin Propanediol23$16,546
Atrovent HfaIpratropium Bromide31$14,676
TrulicityDulaglutide13$12,499
MyrbetriqMirabegron13$12,318
EntrestoSacubitril/Valsartan17$11,966
InvokanaCanagliflozin20$11,353
SteglatroErtugliflozin Pidolate20$10,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$175$57,64269 claims
Lilly USA, LLCTrulicity$19$12,49913 claims
Johnson & JohnsonInvokana$27$11,35320 claims
Sanofi-aventis U.S. LLCLantus$63$1,59612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Bernardino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →